Skip to content

Free cash flow at other companies

Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
-$47.73M-5.0%
iRadimed logo
iRadimedIRMD
$7.89M+1,226%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$48.62M+17.8%
Charles River Laboratories logo
Charles River LaboratoriesCRL
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%

Valuation

See full
Market cap$86.19M-43.5%
Enterprise value$95.86M-31.3%
P/S2.5×-2.5×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Calculated from Rapid Micro Biosystems’s reported figures.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's free cash flow?
Rapid Micro Biosystems (RPID) reported free cash flow of -$15.45M in Q1 2026.
How has Rapid Micro Biosystems's free cash flow changed year-over-year?
Rapid Micro Biosystems's free cash flow decreased by 64.7% year-over-year, from -$9.38M to -$15.45M.
What is the long-term trend for Rapid Micro Biosystems's free cash flow?
Over 4 years (2021 to 2025), Rapid Micro Biosystems's free cash flow has grown at a -13.9% compound annual growth rate (CAGR), from -$58.18M to -$31.91M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.